Novo Nordisk Seeks To Halt Sanofi Insulin Pen

Law360 (September 12, 2007, 12:00 AM EDT) -- Novo Nordisk A/S is asking a New Jersey federal court to stop Sanofi-Aventis sales of recently launched insulin pen SoloStar.

Novo Nordisk filed a motion for a preliminary injunction on Monday that would prevent Sanofi-Aventis and its U.S. affiliate from making and selling SoloStar in the U.S. until the conclusion of its patent infringement case.

Denmark-based drug-maker Novo says SoloStar is threatening its market share for pens and long-lasting insulin.

“Prompt resolution of Novo’s motion for preliminary injunction is essential here because the importation, sale, and...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.